> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Merck’s Ilumya
- URL: https://www.fdaweb.com/regulatory-review-period-for-mercks-ilumya/
- Published: 2020-03-02T12:00:00.000Z
- Updated: 2026-09-14T16:05:17.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146213

*Federal Register* notice: FDA has determined the regulatory review period for patent extension purposes for Merck’s Ilumya (tildrakizumab), indicated for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The review period is 3,452days, which includes 3,089 days that occurred during the testing phase and 363 days during the approval phase. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-04362.pdf?ref=fdaweb.com).